Mylan NV (MYL)

16.11
0.43 2.60
NASDAQ : Health Technology
Prev Close 16.54
Open 16.33
Day Low/High 15.95 / 16.55
52 Wk Low/High 12.75 / 23.11
Volume 5.48M
Avg Volume 6.46M
Exchange NASDAQ
Shares Outstanding 516.95M
Market Cap 8.23B
P/E Ratio 132.75
Div & Yield N.A. (N.A)

My Takeaways and Observations

"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax.   A consecutive nine-day market drop was snapped as we regained most that was lost in that period.   Today was a great day. (Boy, would I like to annualize the pe...

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Biopharma: It's Darkest Before the Dawn

Biopharma: It's Darkest Before the Dawn

Thursday felt a lot like capitulation in this space. I was buying.

My Takeaways and Observations (Early Edition)

I have been warning about weakening breadth and narrow leadership for weeks and months.   What have we gotten? Eight straight days (in a row) down for the first time since 2008.   But, with stocks suffering from election uncertainties and given the ...

Valeant Skyrockets on Rumored $10B Salix Sale

Valeant Skyrockets on Rumored $10B Salix Sale

Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.

McKesson Shares Plunge on Drug Price Cuts

McKesson Shares Plunge on Drug Price Cuts

Shares of the drug distributor were falling sharply Friday.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

Trending Tickers: HSY, RCL, MCK, VRX

Trending Tickers: HSY, RCL, MCK, VRX

Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.

Pharma Should Offer Post-Election Bargains

Pharma Should Offer Post-Election Bargains

The likely continuation of a split government should help the sector recover from its recent beat-down.

Time For Selective Purchases of Health-Care Stocks

Time For Selective Purchases of Health-Care Stocks

With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.

Going on a Mini Biotech Binge Into the Weekend

Thanks to everyone who contributed to the conversation on the Daily Diary today. It was quite a lively bunch. I wish the market could have held earlier highs, but at least it was a positive end to a volatile trading week and a downright brutal one f...

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Morning Movers: SFTBY, AAPL, MYL, DOV, NFLX

Morning Movers: SFTBY, AAPL, MYL, DOV, NFLX

Mylan rose after settling with the U.S. Department of Justice for $465 million over the way it overcharged Medicaid for the EpiPen.

Mylan Overcharged Medicaid by 'Millions of Dollars,' Senators Say

Mylan Overcharged Medicaid by 'Millions of Dollars,' Senators Say

Two U.S. senators claim EpiPen maker Mylan overcharged Medicaid for some twenty years to the tune of millions of dollars.

Mylan's Generic EpiPen Reportedly Ready by End of Year

Mylan's Generic EpiPen Reportedly Ready by End of Year

Mylan's generic EpiPen will come this year, but later than originally expected.

Morning Movers: MYL, DRI, GOOGL and the Pound

Morning Movers: MYL, DRI, GOOGL and the Pound

Brexit concerns pummel the pound while Alphabet gets set to unveil several new devices.

Midday Report: Wells Fargo CEO Under Fire; U.S. Stocks Slide

Midday Report: Wells Fargo CEO Under Fire; U.S. Stocks Slide

U.S. stocks fall into the red by late Thursday morning as Mylan kicks off a selloff in health care.

Closing Bell: Disney Eyes Twitter Buyout; U.S. Stocks Decline Ahead of Debate

Closing Bell: Disney Eyes Twitter Buyout; U.S. Stocks Decline Ahead of Debate

U.S. stocks ended near lows as Wall Street grew restless ahead of the first presidential debate.

Valeant Shares Tumble Before Clinton-Trump Faceoff

Valeant Shares Tumble Before Clinton-Trump Faceoff

Andrew Left says cracking down on Big Pharma may be all that Hillary Clinton and Donald Trump have in common.

Trending Tickers: TWTR, VRX, ENDP, RIG

Trending Tickers: TWTR, VRX, ENDP, RIG

It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.

Andrew Left Says Trump and Clinton Agree on Just One Thing

Andrew Left Says Trump and Clinton Agree on Just One Thing

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.

CEO Isn't All That's Under Pressure at Mylan

CEO Isn't All That's Under Pressure at Mylan

The bear is in control.

Cramer: We Got a Fake-Out From the Fed

Cramer: We Got a Fake-Out From the Fed

And what happened to all those predicting a surprise rate hike?

Morning Movers: MYL, XOM, MSFT, GIS, CLVS

Morning Movers: MYL, XOM, MSFT, GIS, CLVS

Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.

Bank of Japan Takes Surprise Step to Spark Inflation in Policy Revamp

Bank of Japan Takes Surprise Step to Spark Inflation in Policy Revamp

The Bank of Japan introduces a zero percent interest-rate target for 10 year government bonds to step up its fight against deflation.

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.

EpiPen Maker Mylan Gives 'Generous' Executive Pay

EpiPen Maker Mylan Gives 'Generous' Executive Pay

Mylan dealing with more negative reports, this time for executive pay.

Morning Movers: BAYRY, MON, WFC, JPM, MYL

Morning Movers: BAYRY, MON, WFC, JPM, MYL

Bayer has agreed to purchase Monsanto for $66 billion, or $128 a share, a 20% premium over its previous closing price.